AlgiPharma at Partnership Opportunities in Drug Delivery (PODD) Conference 2025, Boston, USA

/in

AlgiPharma attended and presented at this year’s Partnership Opportunities in Drug Delivery (PODD) conference in Boston. Dr. Yngve Mikkelsen (CMO) had the opportunity to present AlgiPharma’s work on alginate oligosaccharides as a next-generation delivery platform for GLP-1 receptor agonists and beyond. Our data demonstrate how AlgiPharma’s technology enhances oral bioavailability and improves mucus translocation for biologics and lipid nanoparticles, opening new frontiers in drug delivery and therapeutic design.

A huge thank you to the organizers for another excellent and engaging event. It was great to reconnect with familiar faces and meet new collaborators across the biotech and pharma landscape and the energy around innovation in drug delivery is inspiring. Attendees from AlgiPharma: CEO, Yngvar Berg, CMO, Yngve Mikkelsen, and CSO, Dr. Philip Rye.

If you couldn’t attend but would like to learn more about our work, don’t hesitate to reach out or visit www.algipharma.com

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma attending the Swedish Pharmaceutical Society meeting at AstraZeneca Mölndal, Sweden

/in

AlgiPharma is attending the 8th International Symposium on Solid Oral Dosage Forms organised by the Swedish Pharmaceutical Society and will take place on 22nd – 25th Sept at the AstraZeneca site in Mölndal, Sweden. Attendees from AlgiPharma will be by our CSO, Dr. Philip Rye, and Dr Ivana Smiljanic our Quality Manager. We are looking forward to expanding our knowledge on aspects of design, production and quality assurance of solid oral dosage forms and how these can impact the development of AlgiPharma’s technology for drug delivery.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com

AlgiPharma attending European Cystic Fibrosis Conference 2025, Milan, Italy

/in

AlgiPharma is attending the European Cystic Fibrosis Conference taking place on 4th – 6th June in Milan Italy. Looking forward to catching up with CF colleagues and using the opportunity for further discussions with potential commercial partners. Attendees from AlgiPharma will be our CEO, Yngvar Berg, CSO, Dr. Philip Rye, and Dr Charles Johnson from our board of directors.

 

About AlgiPharma AS:

AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:

  • Delivery platforms for nanoparticles, small and large molecule based drugs.
  • Drug conjugates, adding functionality and reducing toxicity of parent compound.
  • API in disease areas such as cystic fibrosis, COPD, and infectious diseases.

AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.

 

AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.

AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).

AlgiPharma is a privately owned company registered and domiciled in Norway.

For additional information contact:

Yngvar P. Berg, CEO: yngvar.berg@algipharma.com

Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com